Tuesday, August 29, 2023
BridGene Biosciences, Inc. has made a significant advancement in its collaboration with Takeda, a biopharmaceutical company. The company employs a proprietary technology called IMTAC™ (Isobaric Mass Tagged Affinity Characterization), which focuses on identifying new targets for neurodegenerative disorders. Through this partnership, BridGene has achieved a crucial preclinical milestone and is set to receive a milestone payment whose amount remains undisclosed.
Dr. Ping Cao, the CEO and Co-Founder of BridGene Biosciences, expressed his satisfaction with the progress made in the collaboration. He emphasized the effectiveness of the IMTAC platform and the strong working relationship that has developed between BridGene and Takeda.
BridGene follows a distinct approach to drug discovery and development. This approach involves the use of covalent small molecules to target traditionally challenging areas, along with the application of chemoproteomics to study interactions between these molecules and proteins in live cells. This unique methodology enables BridGene to rapidly identify drug targets within living cells and gain insights into the disease characteristics that these targets influence.
This achievement is a continuation of BridGene's earlier success in March 2023 when it reached its first preclinical milestone under the 2021 agreement with Takeda. This agreement aims to create several drug discovery initiatives using the IMTAC platform.
